Effect of intravesical bupivacaine on the urinary catheter related bladder discomfort

Evaluation of the effect of diluted intravesical bupivacaine on the urinary catheter related bladder discomfort during recovery from anesthesia in young males

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014090111398N6

Enrollment

Registered

2014-09-23

Start date

2014-10-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urinary catheter related bladder discomfort. Foreign body in bladder

Interventions

Intervention 1: In intervention group: Infusion of 50 ml Bupivacaine 0.2% into bladder via urinary catheter 15 min before awakening from anesthesia. Intervention 2: In control group: Infusion of 50 ml

Prevention

In intervention group: Infusion of 50 ml Bupivacaine 0.2% into bladder via urinary catheter 15 min before awakening from anesthesia

In control group: Infusion of 50 ml normal saline as placebo into bladder via urinary catheter 15 min before awakening from anesthesia

Eligibility

Sex/Gender

Male

Age

18 Years to 59 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: male gender, 18-60 years old, candidated for surgery under general anesthesia, having indication for urinary catheter insertion, ASA physical class I & II, and agreement for participation in the study Exclusion criteria: female gender, age less than 18 and more than 60, no indication for bladder catheterization during surgery, ASA class more than II, no agreement for participation, addiction to opiates and other drugs abusers, patients with kidney and urinary tract diseases and intra pelvic & lower abdomen surgeries.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Severity of patient's bladder discomfort in recovery. Timepoint: Every 15 min after arrival of patients to recovery until 30 min. Method of measurement: Patient's own report and question from them.;Severity of patient's agitation. Timepoint: Every 15 min after arrival of patients to recovery until 30 min. Method of measurement: Observation by recovery room nurse.	—

Secondary

Measure	Time frame
Amount of fentanyl usage. Timepoint: Discharge time from recovery. Method of measurement: Sum of the drug usage.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Reza Ghodraty MD.

Iran University of Medical Sciences

mrghodrati@yahoo.comghodrati.mr@iums.ac.ir+98 21 8894 6762

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026